Takeshi Masumoto - Hisamitsu Pharmaceutical Director
| HTSUF Stock | USD 25.22 0.00 0.00% |
Director
Takeshi Masumoto is Executive Officer, Director of Kinki Supervision Unit in Pharmaceutical Business Unit of Hisamitsu Pharmaceutical Co since 2015.
| Tenure | 9 years |
| Phone | 81 3 5293 1720 |
| Web | https://www.hisamitsu.co.jp |
Hisamitsu Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0212 % which means that it generated a profit of $0.0212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0504 %, meaning that it generated $0.0504 on every $100 dollars invested by stockholders. Hisamitsu Pharmaceutical's management efficiency ratios could be used to measure how well Hisamitsu Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 219 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Hisamitsu Pharmaceutical has a current ratio of 4.37, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hisamitsu Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Hisamitsu Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hisamitsu Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hisamitsu to invest in growth at high rates of return. When we think about Hisamitsu Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Iris Yahal | Formula Systems 1985 | 53 | |
| Clyde Patterson | Home Federal Bancorp | 74 | |
| Eduardo Szymanski | Betterware De Mexico | N/A | |
| John Bosen | Provident Bancorp | 49 | |
| Eliyahu Zamir | Formula Systems 1985 | 46 | |
| Lisa DeStefano | Provident Bancorp | N/A | |
| Woodus Humphrey | Home Federal Bancorp | 77 | |
| Andrew Hack | Mersana Therapeutics | 43 | |
| Timothy Wilhite | Home Federal Bancorp | 48 | |
| Rafal Kozlowski | Formula Systems 1985 | 41 | |
| Richard Peeke | Provident Bancorp | 69 | |
| Willard Dere | Mersana Therapeutics | 64 | |
| Lawrence Alleva | Mersana Therapeutics | 67 | |
| Eliahu Zamir | Formula Systems 1985 | 47 | |
| Elizabeth Donnelly | Marker Therapeutics | N/A | |
| Frank Cousins | Provident Bancorp | 55 | |
| Grant Chamberlain | Immutep Ltd ADR | N/A | |
| David Herndon | Home Federal Bancorp | 79 | |
| Jay Gould | Provident Bancorp | N/A | |
| Walter Colquitt | Home Federal Bancorp | 72 | |
| Dafna Cohen | Formula Systems 1985 | 45 | |
Management Performance
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 |
Hisamitsu Pharmaceutical Leadership Team
Elected by the shareholders, the Hisamitsu Pharmaceutical's board of directors comprises two types of representatives: Hisamitsu Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hisamitsu. The board's role is to monitor Hisamitsu Pharmaceutical's management team and ensure that shareholders' interests are well served. Hisamitsu Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hisamitsu Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hirotaka Nakatomi, Chairman, CEO and Chairman of Crisis Management Committee | ||
| Hidenori Hadate, Senior Managing Executive Officer | ||
| Tsuyoshi Ayabe, Executive Officer, Manager of Corporate Strategy Office | ||
| Toshiaki Tsuruda, Executive Officer, Chief Director of Production Environment, Director | ||
| Toshihide Kanari, Executive Officer, Director of External Affairs, Manager of Public Relations Office | ||
| Teijiro Furukawa, Non-Executive Independent Director | ||
| Takeshi Shakata, Executive Officer, Director of Drug and Cosmetics Business | ||
| Akira Kawata, Executive Officer | ||
| Shinichiro Takao, General Manager of IR Department, Treasurer and Director | ||
| Nobuo Tsutsumi, Executive Officer, Director of Legal Affairs, Director | ||
| Hiroyuki Taketomi, Executive Officer, Senior Director of Manufacturing, Director of General Affairs in Tosu Plant, Tosu Plant Manager | ||
| Katsuhiko Akiyama, Executive Officer, Director of Development Planning, Director of Base Research Institute | ||
| Tetsuo Akiyama, Managing Director and Director | ||
| Takeshi Masumoto, Executive Officer, Director of Kinki Supervision Unit in Pharmaceutical Business Unit | ||
| Kazuhide Nakatomi, President, COO and Executive VP | ||
| Isao Ichikawa, Non-Executive Independent Director | ||
| Shinichi Murayama, Executive Officer, Manager of President's Office in Kyushu Headquarters, Director | ||
| Akira Kayashima, Executive Officer | ||
| Mitsumasa Kabashima, Pres Ltd | ||
| Kyu Saito, Executive Officer, Director of International Business, Chairman of Subsidiaries, Director | ||
| Kiyotaka Takada, Executive Officer, Director of Production Technology Development | ||
| Mitsutoshi Tsuruta, Ex Division | ||
| Hidenao Minami, Executive Officer, Director of Clinical Development | ||
| Masaya Okuno, OTC Division | ||
| Takaaki Terahara, Executive Officer, Director of TDDS Research Institute, Manager of New Basic Technology Research Office, Manager of Patent Application Office | ||
| Naruhito Higo, Head of Research and Managing Director | ||
| Kotaro Sugimura, Executive Officer, Chief Director of Business, Manager of 1st Tokyo Office | ||
| Koji Takiyama, Executive Officer, Manager of President's Office | ||
| Kosuke Sugiyama, Senior Managing Director, Executive Officer, Director of Human Resource |
Hisamitsu Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hisamitsu Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.15 B | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 26.45 % | |||
| Shares Owned By Institutions | 35.26 % | |||
| Price To Earning | 22.53 X | |||
| Price To Book | 0.97 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hisamitsu Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hisamitsu Pharmaceutical's short interest history, or implied volatility extrapolated from Hisamitsu Pharmaceutical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Hisamitsu Pink Sheet analysis
When running Hisamitsu Pharmaceutical's price analysis, check to measure Hisamitsu Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hisamitsu Pharmaceutical is operating at the current time. Most of Hisamitsu Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Hisamitsu Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hisamitsu Pharmaceutical's price. Additionally, you may evaluate how the addition of Hisamitsu Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |